Acid Reflux Disease

AstraZeneca Announces NEXIUM(R)(esomeprazole magnesium) Savings Program for Purple Plus(TM) Members

Published in Healthcare Finance, Tax and Law Weekly, November 21st, 2007

AstraZeneca (NYSE:AZN) announced the enhancements to the Purple Plus(TM) Program for patients with gastroesophageal reflux disease (GERD) who are prescribed NEXIUM(R) (esomeprazole magnesium). This patient support program is designed to make NEXIUM more affordable for patients through instant rebates, and to provide educational tools that can assist patients in staying adherent to their prescribed therapy.

"NEXIUM is a very important treatment option for patients with GERD because of its proven efficacy in healing damage to the esophagus caused by acid reflux," said Doug Levine, MD, Executive Director in Clinical Development for AstraZeneca. "As part of our...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly

Source: Healthcare Finance, Tax and Law Weekly (2007-11-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry